Morgan Stanley maintains an 'Equalweight' rating for HENGAN INT'L due to expected moderate revenue growth driven by tissue paper sales, despite pressure on average selling prices from online and new retail channels. The company is committed to a stable dividend, which supports its share price, but challenges in other segments like sanitary napkins and diapers, along with a lack of strong revenue acceleration, limit the potential for a higher valuation.
